Adimab, LLC

Also on record

Records under this name other than the patents Adimab, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 32 patents it holds.

Back to Adimab, LLC

Patent	Title	Status	Expires	Confidence
US 10,308,718	Anti-Sortilin Antibodies and Methods of Use Thereof conveyed to Alector LLC In force Term ends Apr 7, 2036 · High confidence	In force	Term ends Apr 7, 2036	High confidence
US 11,208,488	Methods of Increasing Progranulin Levels Using Anti-Sortilin Antibodies conveyed to Alector LLC In force Term ends Apr 7, 2036 · High confidence	In force	Term ends Apr 7, 2036	High confidence
US 11,339,223	Methods of Use of Anti-Sortilin Antibodies for Treating a Disease, Disorder, or Injury conveyed to Alector LLC In force Term ends Apr 7, 2036 · High confidence	In force	Term ends Apr 7, 2036	High confidence
US 11,186,645	Isolated Nucleic Acids Encoding Anti-Sortilin Antibodies conveyed to Alector LLC In force Term ends May 10, 2036 · High confidence	In force	Term ends May 10, 2036	High confidence
US 11,398,771	Switching Regulator Control Circuit Enabling Fault Protection Operation, Current-Mode-Control Switching Power Supply Device, and Vehicle conveyed to Compass Therapeutics LLC In force Term ends Dec 27, 2036 · Medium confidence	In force	Term ends Dec 27, 2036	Medium confidence
US 10,053,515	Anti-Coagulation Factor XI Antibodies now held by Merck Sharp & Dohme LLC In force Term ends Jan 19, 2037 · High confidence	In force	Term ends Jan 19, 2037	High confidence
US 10,584,179	Anti-Coagulation Factor XI Antibodies now held by Merck Sharp & Dohme LLC In force Term ends Jan 25, 2037 · High confidence	In force	Term ends Jan 25, 2037	High confidence
US 10,307,455	Activin Type 2 Receptor Antibodies now held by Acceleron Pharma Inc. In force Term ends Mar 10, 2037 · High confidence	In force	Term ends Mar 10, 2037	High confidence
US 11,000,565	Methods of Increasing Muscle Mass by Administration of Activin Type 2 Receptor Antibodies now held by Acceleron Pharma Inc. In force Term ends Mar 10, 2037 · High confidence	In force	Term ends Mar 10, 2037	High confidence
US 10,689,450	Bcma Binding Molecules and Methods of Use Thereof now held by Kite Pharma, Inc. In force Term ends Mar 31, 2037 · High confidence	In force	Term ends Mar 31, 2037	High confidence

10 of 141 records shown.

Pro members see all 141.

Pro members: see all 141 records